Evidence map›Paper›PMID 29464079›Full record

ArticleOncotarget2018

Differential tumor biological role of the tumor suppressor KAI1 and its splice variant in human breast cancer cells.

Julia Miller, Tobias F Dreyer, Anne Sophie Bächer, Eva-Kathrin Sinner, Christine Heinrich, Anke Benge, Eva Gross, Sarah Preis, Jan Rother, Anthony Roberts and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Julia MillerDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Tobias F DreyerDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Anne Sophie BächerDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Eva-Kathrin SinnerBOKU, University of Natural Resources and Life Sciences, 1180 Vienna, Austria.
Christine HeinrichDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Anke BengeDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Eva GrossDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Sarah PreisDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Jan RotherMaterials Science Laboratory, Sony Europe Ltd ZN Deutschland, D-70327 Stuttgart, Germany.
Anthony RobertsMaterials Science Laboratory, Sony Europe Ltd ZN Deutschland, D-70327 Stuttgart, Germany.
Gabriele NellesMaterials Science Laboratory, Sony Europe Ltd ZN Deutschland, D-70327 Stuttgart, Germany.
Tzenka MitevaMaterials Science Laboratory, Sony Europe Ltd ZN Deutschland, D-70327 Stuttgart, Germany.
Ute ReuningDepartment for Obstetrics & Gynecology, Technical University of Munich, D-81675 Munich, Germany.
Technical University of Munich · DEBOKU University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tetraspanin and tumor suppressor KAI1 is downregulated or lost in many cancers which correlates with poor prognosis. KAI1 acts via physical/functional crosstalk with other membrane receptors. Also, a splice variant of KAI1 (KAI1-SP) has been identified indicative of poor prognosis. We here characterized differential effects of the two KAI1 variants on tumor biological events involving integrin (αvß3) and/or epidermal growth factor receptor (EGF-R). In MDA-MB-231 and -435 breast cancer cells, differential effects were documented on the expression levels of the tumor biologically relevant integrin αvß3 which colocalized with KAI1-WT but not with KAI1-SP. Cellular motility was assessed by video image processing, including motion detection and vector analysis for the quantification and visualization of cell motion parameters. In MDA-MB-231 cells, KAI1-SP provoked a quicker wound gap closure and higher closure rates than KAI1-WT, also reflected by different velocities and average motion amplitudes of singular cells. KAI1-SP induced highest cell motion adjacent to the wound gap borders, whereas in MDA-MB-435 cells a comparable induction of both KAI1 variants was noticed. Moreover, while KAI1-WT reduced cell growth, KAI1-SP significantly increased it going along with a pronounced EGF-R upregulation. KAI1-SP-induced cell migration and proliferation was accompanied by the activation of the focal adhesion and Src kinase. Our findings suggest that splicing of KAI1 does not only abrogate its tumor suppressive functions, but even more, promotes tumor biological effects in favor of cancer progression and metastasis.

Indexed as

breast cancercell motion vector analysiscell proliferation/adhesion/migrationintegrin avβ3tumor suppressor KAI1 (CD82)

Identifiers

PMID29464079
PMCPMC5814219
OpenAlexW2782362307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.